| 1 |
Diamandis EP. Theranos phenomenon – part 4: Theranos at an International Conference. Clinical Chemistry and Laboratory Medicine (CCLM) 2016;54. [DOI: 10.1515/cclm-2016-0389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 2 |
Moschou D, Tserepi A. The lab-on-PCB approach: tackling the μTAS commercial upscaling bottleneck. Lab Chip 2017;17:1388-405. [DOI: 10.1039/c7lc00121e] [Cited by in Crossref: 71] [Cited by in F6Publishing: 21] [Article Influence: 14.2] [Reference Citation Analysis]
|
| 3 |
Nichols ZE, Geddes CD. Sample Preparation and Diagnostic Methods for a Variety of Settings: A Comprehensive Review. Molecules 2021;26:5666. [PMID: 34577137 DOI: 10.3390/molecules26185666] [Reference Citation Analysis]
|
| 4 |
Fiala C, Diamandis EP. Can Grail find the trail to early cancer detection? Clin Chem Lab Med 2019;57:403-6. [PMID: 30530899 DOI: 10.1515/cclm-2018-1249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
Fiala C, Diamandis EP. The Outcomes of Scientific Debates Should Be Published: The Arivale Story. J Appl Lab Med 2020;5:1070-5. [PMID: 32830260 DOI: 10.1093/jalm/jfaa110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 6 |
Nakra N, Pandey M. Smartphone as an intervention to intention-behavior of patient care. Health Policy and Technology 2019;8:143-50. [DOI: 10.1016/j.hlpt.2019.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 7 |
Pedlar CR, Newell J, Lewis NA. Blood Biomarker Profiling and Monitoring for High-Performance Physiology and Nutrition: Current Perspectives, Limitations and Recommendations. Sports Med 2019;49:185-98. [PMID: 31691931 DOI: 10.1007/s40279-019-01158-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 8 |
Young CC, Ippolito DL. Far-Forward Diagnostics in Toxic Industrial Chemical and Material Exposure Scenarios and Biomarker Identification. J Occup Environ Med 2017;59:e204-8. [PMID: 28692011 DOI: 10.1097/JOM.0000000000001083] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 9 |
Sher M, Zhuang R, Demirci U, Asghar W. Paper-based analytical devices for clinical diagnosis: recent advances in the fabrication techniques and sensing mechanisms. Expert Rev Mol Diagn 2017;17:351-66. [PMID: 28103450 DOI: 10.1080/14737159.2017.1285228] [Cited by in Crossref: 142] [Cited by in F6Publishing: 110] [Article Influence: 28.4] [Reference Citation Analysis]
|
| 10 |
Fiala C, Diamandis EP. The meteoric rise and dramatic fall of Theranos: lessons learned for the diagnostic industry. Clinical Chemistry and Laboratory Medicine (CCLM) 2018;56:1443-6. [DOI: 10.1515/cclm-2018-0353] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Yip P, Venner A, Shea J, Fuezery A, Huang Y, Massicotte L, Tetreault N, Tomalty C, Shaw J. Point-of-care testing: A position statement from the Canadian Society of Clinical Chemists. Clinical Biochemistry 2018;53:156-9. [DOI: 10.1016/j.clinbiochem.2018.01.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
